# Long Term Open Label Continuation Study

> **NCT00195650** · PHASE3 · COMPLETED · sponsor: **Abbott** · enrollment: 846 (actual)

## Conditions studied

- Rheumatoid Arthritis

## Interventions

- **BIOLOGICAL:** Adalimumab

## Key facts

- **NCT ID:** NCT00195650
- **Lead sponsor:** Abbott
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2000-07
- **Primary completion:** 2011-05
- **Final completion:** 2011-05
- **Target enrollment:** 846 (ACTUAL)
- **Last updated:** 2012-08-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00195650

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00195650, "Long Term Open Label Continuation Study". Retrieved via AI Analytics 2026-07-18 from https://api.ai-analytics.org/clinical/NCT00195650. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*